← Leaderboards
Thomas A Russo
Va Western New York Healthcare System
$3,615,549
Attributed
$4,106,397
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $981.7K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,106,397 · 6
VA$0 · 2
By mechanism
R01$1,818,518 · 2
R21$1,306,182 · 3
R56$981,697 · 1
I01$0 · 2
Top collaborators
- Margaret A. Phillips1 shared
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionEscherichia ColiResistancePathogenAntimicrobialReportingIn VivoAntimicrobial ResistanceBaseAbscessAcinetobacter BaumanniiHealthcareLocationPathogenicityPneumoniaAffectIncidenceStructureProductionTraitIn VitroExtensive Drug ResistanceInsightMonoclonal Antibodies
Grant awards (23)
Determining the value of PBP 7/8 as an antimicrobial target for XDR-A. baumannnii$0
I01 · FY2025 · VA · contact PI
Determining the value of PBP 7/8 as an antimicrobial target for XDR-A. baumannnii$0
I01 · FY2024 · VA · contact PI
Determining the value of PBP 7/8 as an antimicrobial target for XDR-A. baumannnii$0
I01 · FY2023 · VA · contact PI
Determining the value of PBP 7/8 as an antimicrobial target for XDR-A. baumannnii$0
I01 · FY2022 · VA · contact PI
Identification of new or unrecognized virulence genes in hypervirulent Klebsiella pneumoniae and antivirulence genes in classical K. pneumoniae.$235,744
R21 · FY2021 · AI · contact PI
Determining the value of PBP 7/8 as an antimicrobial target for XDR-A. baumannnii$0
I01 · FY2021 · VA · contact PI
Identification of new or unrecognized virulence genes in hypervirulent Klebsiella pneumoniae and antivirulence genes in classical K. pneumoniae.$195,938
R21 · FY2020 · AI · contact PI
Determining the value of PBP 7/8 as an antimicrobial target for XDR-A. baumannnii$0
I01 · FY2020 · VA · contact PI
DHODH Inhibitors: A Potential New Class of Antimicrobials for Treatment of the Drug Resistant Gram-Negative Bacillus Acinetobacter baumannii$981,697
R56 · FY2018 · AI · contact PI
Development of a diagnostic test for hypervirulent Klebsiella pneumoniae$199,375
R21 · FY2017 · AI · contact PI
Development of a diagnostic test for hypervirulent Klebsiella pneumoniae$239,250
R21 · FY2016 · AI · contact PI
Analysis of A Baumannii Capsule as a Vaccine Candidate$0
I01 · FY2014 · VA · contact PI
Analysis of A Baumannii Capsule as a Vaccine Candidate$0
I01 · FY2013 · VA · contact PI
Identification of genes essential for survival of hypervirulent Kleb. pneumoniae$198,125
R21 · FY2012 · AI · contact PI
Analysis of A Baumannii Capsule as a Vaccine Candidate$0
I01 · FY2012 · VA · contact PI
Identification of genes essential for survival of hypervirulent Kleb. pneumoniae$237,750
R21 · FY2011 · AI · contact PI
Analysis of A Baumannii Capsule as a Vaccine Candidate$0
I01 · FY2011 · VA · contact PI
BACTERIAL MODULATION OF LUNG INFLAMMATORY RESPONSE$353,250
R01 · FY2004 · HL
BACTERIAL MODULATION OF LUNG INFLAMMATORY RESPONSE$353,250
R01 · FY2003 · HL
BACTERIAL MODULATION OF LUNG INFLAMMATORY RESPONSE$351,000
R01 · FY2002 · HL
BACTERIAL MODULATION OF LUNG INFLAMMATORY RESPONSE$348,750
R01 · FY2001 · HL
E COLI URINARY TRACT INFECTION--BIOLOGY AND PREVENTION$209,150
R01 · FY2001 · AI
E COLI URINARY TRACT INFECTION--BIOLOGY AND PREVENTION$203,118
R01 · FY2000 · AI